I research prognostic factors related to stroke (hemorrhagic or ischemic) during ongoing anticoagulant therapy, as well as reversal strategies concerning intracerebral hemorrhage.

Study I: Prognosis for intracerebral hemorrhage during ongoing anticoagulant treatment

Intracerebral hemorrhage (ICH) is the most serious adverse effect of treatment with oral anticoagulants. Prognostic data after ICH associated with novel oral anticoagulants (NOAC) compared to vitamin-K antagonists (VKA) are sparse. We compared 90-day survival and functional outcome following NOAC-ICH versus VKA-ICH using data from the Swedish Stroke Register (Riksstroke) between 2012-2016.

Study II: Functional outcome and mortality following antithrombotic associated intracerebral hemorrhage

Antithrombotic treatments, including antiplatelet (AP), oral anticoagulant (OAC) and thrombolytic drugs, increase the risk of intracerebral hemorrhage (ICH). In the event of an ICH, many suggest that prior use of antithrombotics lead to hematoma expansion, resulting in increased mortality. The relationship between antithrombotic use and increased functional dependency and mortality following ICH is studied in this article and compared to nonantithrombotic associated ICH. Studies have previously shown ambiguous results concerning antithrombotic drugs as independent predictors of functional status and mortality outcome following ICH. The incidence of ICH (ICD.10 i61) in Sweden between 2012-2017 is also analysed in this study.